A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL)
November 24, 2025 updated by: Novo Nordisk A/S
Semaglutide Cardiovascular Outcomes Trial in Patients With Type 2 Diabetes
The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease.
Participants will either get semaglutide tablets or placebo tablets ("dummy" medicine) - which treatment is decided by chance.
Participants must take one tablet with water every morning on an empty stomach and not eat or drink anything for at least 30 minutes.
The study will last for about 3.5-5 years.
Participants will have up to 25 clinic visits and 1 phone call with the study doctor.
Women cannot be in the study if pregnant, breast-feeding or if they plan to become pregnant during the study period.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
9651
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Algiers, Algeria, 16000
- Internal medicine department
-
Constantine, Algeria, 25000
- endocrino-diabetology department, Hospital IBN BADIS.
-
Constantine, Algeria, 25000
- Internal Medecine department CHU Ibn Badis
-
Oran, Algeria, 31000
- EHU 1st November 1954
-
Oran, Algeria, 31000
- Internal Medicine departement CHU Oran
-
Sétif, Algeria, 19000
- Department of internal of medicine, CHU Setif
-
-
-
-
-
Buenos Aires, Argentina, C1181ACH
- Hospital Italiano
-
Buenos Aires, Argentina, B1704ETD
- DIM Clinica Privada
-
Buenos Aires, Argentina, B6000BHA
- Centro Medico Lebensohn
-
Capital Federal, Argentina, C1056ABI
- Centro de Investigaciones Metabólicas
-
Córdoba, Argentina, X5003DCE
- Instituto Medico Damic
-
Córdoba, Argentina, X5006IKK
- Centro Médico Privado San Vicente Diabetes
-
Córdoba, Argentina, 5008
- Centro Médico Privado CEMAIC
-
Córdoba, Argentina, 5000
- Centro Diabetologico Cordoba Dr. Waitman
-
Lanús Este, Argentina, B1824KAJ
- Centro Médico CIMEL
-
Mar del Plata, Argentina, B7600FZN
- Instituto de Investigaciones Clinicas
-
Rosario, Santa Fe, Argentina, S2000CVB
- Sanatorio Britanico S.A.
-
-
Buenos Aires
-
Lanús Este, Buenos Aires, Argentina, B1824KAJ
- Centro Médico CIMEL
-
-
-
-
-
Graz, Austria, 8036
- Univ.-Klinik für Innere Medizin
-
Innsbruck, Austria, 6020
- Medizinische Universität Innsbruck
-
Saint Stefan, Austria, 8511
- Fließer-Görzer [Ordination]
-
Vienna, Austria, 1160
- Klinik Ottakring
-
Vienna, Austria, 1130
- Klinik Hietzing
-
-
-
-
-
Bonheiden, Belgium, 2820
- Imeldaziekenhuis - Bonheiden - Department of Endocrinology
-
Edegem, Belgium, 2650
- UZA - UZ Antwerpen - Department of Endocrinology
-
Edegem, Belgium, 2650
- UZ Antwerpen - UZA - Department of Endocrinology
-
Ghent, Belgium, 9000
- UZ Gent - Endocrinologie - Diabetologie
-
Kortrijk, Belgium, 8500
- AZ Groeninge - Kortrijk - Centrum Endo - Diabetologie
-
Leuven, Belgium, 3000
- UZ Leuven - Endocrinology
-
Roeselare, Belgium, 8800
- AZ Delta - Roeselare - Diabeteskliniek
-
Roeselare, Belgium, 8800
- AZ Delta - Roeselare
-
-
-
-
Federal District
-
Brasília, Federal District, Brazil, 70390-700
- Hospital do Coracao do Brasil
-
-
Paraná
-
Curitiba, Paraná, Brazil, 80030-480
- Cline Research Center
-
Curitiba, Paraná, Brazil, 80045-110
- Quanta Diagnóstico Nuclear / Medicina Nuclear Alto da XV
-
-
Rio Grande do Sul
-
Passo Fundo, Rio Grande do Sul, Brazil, 99010-080
- Hospital São Vicente de Paulo
-
-
São Paulo
-
Campinas, São Paulo, Brazil, 13060-080
- Instituto de Pesquisa Clínica de Campinas
-
Campinas, São Paulo, Brazil, 13092-133
- i9 Pesquisas Clínicas
-
São Paulo, São Paulo, Brazil, 01228-200
- CPCLIN - Centro de Pesquisas Clínicas
-
São Paulo, São Paulo, Brazil, 01228-000
- Cpquali Pesquisa Clinica Ltda
-
São Paulo, São Paulo, Brazil, 01223-001
- Instituto de Pesquisa Clinica (IPEC)
-
-
-
-
-
Québec, Canada, G1V 4G2
- CHU de Quebec-Universite Laval
-
-
Alberta
-
Calgary, Alberta, Canada, T2V 4J2
- C-endo Diab Endo Clin Calgery
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Vancouver General Hospital_Vancouver_0
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Nova Scotia Hlth Halifax
-
-
Ontario
-
Barrie, Ontario, Canada, L4N 7L3
- LMC Diabetes & Endocrinology (Barrie)
-
Brampton, Ontario, Canada, L6T 0G1
- Aggarwal and Assoc Ltd.
-
Brampton, Ontario, Canada, L6S 0C6
- LMC ClinRsrh Inc.Brampton
-
Concord, Ontario, Canada, L4K 4M2
- LMC Clinical Res Thornhill
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster University
-
Hamilton, Ontario, Canada, L8M 1K7
- Premier Clinical Trial Research Network (PCTRN)
-
Markham, Ontario, Canada, L3P 7P2
- My Endo Diabetes & Endo Cent
-
Sarnia, Ontario, Canada, N7T 4X3
- Bluewater Clin Res Group, Inc.
-
Sarnia, Ontario, Canada, N7T 4X3
- Bluewater Clin Res Group,Inc
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
Toronto, Ontario, Canada, M6G 1M2
- Diabetes Heart Research Centre
-
Toronto, Ontario, Canada, M5G 2N2
- UHN-Toronto General Hospital
-
-
Quebec
-
Mirabel, Quebec, Canada, J7J 2K8
- Manna Research Mirabel
-
Montreal, Quebec, Canada, H4A 3T2
- Applied Med Inf Res
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100044
- Peking University People's Hospital-Endocrinology
-
-
Hebei
-
Cangzhou, Hebei, China, 061000
- Cangzhou People's Hospital
-
Cangzhou, Hebei, China, 061000
- Cangzhou People's Hospital-Endocrinology
-
-
Jiangsu
-
Changzhou, Jiangsu, China, 213003
- Changzhou No.2 People's Hospital, Yanghu Branch
-
Zhenjiang, Jiangsu, China, 212001
- The Affiliated Hospital of Jiangsu University_Zhenjiang
-
Zhenjiang, Jiangsu, China, 212001
- The Affiliated Hospital of Jiangsu University-Endocrinology
-
-
Shandong
-
Jinan, Shandong, China, 250013
- Jinan Central Hospital Affiliated to Shandong University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200240
- Shanghai Fifth People's Hospital-Endocrinology
-
-
-
-
-
Barranquilla, Colombia, 80020
- Clinica De La Costa
-
Pasto, Colombia, 520002
- Fundación Centro de Obesidad y Metabolismo COMETA
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 80020
- Clinica De La Costa
-
-
Barranquilla
-
Soledad, Barranquilla, Colombia, 83001
- Fundación Hospital Universidad del Norte
-
-
Santander Department
-
Bucaramanga-piedecuesta, Valle Del Menzuli - Santander, Santander Department, Colombia, 681012
- Unidad de Estudios Clínicos de la Fundación Cardiovascular de Colombia
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760032
- Fundacion Valle Del Lili
-
-
-
-
-
Krapinske Toplice, Croatia, 49217
- Specijalna Bolnica Za Medicinsku Rehabilitaciju Krapinske Toplice
-
Osijek, Croatia, 31 000
- Klinicki Bolnicki Centar Osijek
-
Pula, Croatia, 52100
- Opca bolnica Pula
-
Rijeka, Croatia, 51000
- KBC Rijeka, Zavod za endokrinologiju
-
Split, Croatia, 21 000
- KBC Split / Krizine / Dijabetes
-
Varaždin, Croatia, 42 000
- Opca bolnica Varazdin_Endocrinology
-
Zadar, Croatia, 23000
- Opca bolnica Zadar_Endocrinology
-
Zagreb, Croatia, 10 000
- KB Merkur - Sveucilisna klinika Vuk Vrhovac
-
Zagreb, Croatia, 10000
- KB Dubrava, Zavod za endokrinologiju i dijabetes
-
-
City of Zagreb
-
Zagreb, City of Zagreb, Croatia, 10000
- Poliklinika Solmed
-
-
-
-
-
Brno, Czechia, 602 00
- Fakultni nemocnice u sv. Anny v Brne
-
Chrudim, Czechia, 53701
- Intendia klinika
-
Hradec Králové, Czechia, 500 05
- FN Hradec Kralove
-
Moravská Ostrava, Czechia, 70200
- Diabetologicka a Interni Ambulance MUDr. Jan Vrkoc s.r.o.
-
Ostrava, Czechia, 73000
- Ambulance DIA - INTERNA s.r.o.
-
Pilsen, Czechia, 30100
- Diabetologicka ambulance Plzen
-
Pilsen, Czechia, 326 00
- MUDr. Jitka Zemanova - diabetologie a interna, s.r.o.
-
Plzeň - Východní Předměstí, Czechia, 32600
- MUDr. Jitka Zemanova diabetologie a interna
-
Plzeň 3, Czechia, 301 00
- DIALINE s.r.o.
-
Prague, Czechia, 14021
- Institut klinicke a experimentalni mediciny_Praha
-
-
-
-
-
Aarhus N, Denmark, 8200
- Aarhus Universitetshospital, Steno Diabetes Center Aarhus
-
Copenhagen, Denmark, 2400
- Bispebjerg Hospital, IC-Forskning
-
Hillerød, Denmark, 3400
- Hillerød Endokrinologisk amb. H0652
-
Slagelse, Denmark, 4200
- Slagelse Sygehus Ambulatorium for hjertesygdomme
-
Svendborg, Denmark, 5700
- Svendborg Sygehus - Endokrinologisk afdeling
-
-
-
-
-
Besançon, France, 25030
- Centre Hospitalier Universitaire de Besancon-Hopital Jean Minjoz
-
Dijon, France, 21079
- Centre Hospitalier Universitaire de Dijon-Hopital Le Bocage
-
Le Coudray, France, 28630
- Les Hopitaux de Chartres-Hopital Louis Pasteur
-
Marseille, France, 13005
- Assistance Publique Hopitaux de Marseille-Hopital de La Conception
-
Narbonne, France, 11100
- Centre Hospitalier de Narbonne
-
Paris, France, 75877
- Ap-Hp-Hopital Bichat-Claude Bernard-1
-
Pessac, France, 33600
- Centre Hospitalier Universitaire de Bordeaux-Hopital Haut Leveque-2
-
Strasbourg, France, 67098
- Les Hopitaux Universitaires de Strasbourg-Hopital de Hautepierre-1
-
-
-
-
-
Dresden, Germany, 01307
- Uniklinik TU Dresden - Med. Klinik III
-
Dresden, Germany, 01277
- Cardiologicum Dresden und Pirna - MVZ "Am Felsenkeller" (Dresden)
-
Essen, Germany, 45219
- Praxis Dr. med. M. Esser
-
Falkensee, Germany, 14612
- Zentrum für klinische Forschung, Dr. med. Lüdemann
-
Hamburg, Germany, 22041
- Diabetes Zentrum Wandsbek Berufsausuebungsgemeinschaft GbR
-
Hamburg, Germany, 21073
- Diabetologische Schwerpunktpraxis Harburg- Dr. med.Paschen,
-
Jerichow, Germany, 39319
- Praxisgemeinschaft Jerichow
-
Lingen, Germany, 49808
- Diabetologische Gemeinschaftspraxis Dr. Staudenmeyer und Dr. Schiwietz
-
Ludwigshafen, Germany, 67059
- Die Praxis am Ludwigsplatz
-
Münster, Germany, 48145
- Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
-
Oldenburg in Holstein, Germany, 23758
- RED-Institut für medizinische Forschung und Fortbildung GmbH
-
Rehlingen-Siersburg, Germany, 66780
- Praxis Dr. med. Wenzl-Bauer
-
Stuttgart, Germany, 70199
- VvP Kliniken gGmbH Marienhospital Stuttgart - Innere Medizin I
-
Witten, Germany, 58455
- Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann
-
-
-
-
-
Shatin, New Territories, Hong Kong
- Prince of Wales Hospital
-
-
-
-
-
New Delhi, India, 110001
- Lady Hardinge Medical College
-
New Delhi, India, 110085
- North Delhi Diabetes Centre
-
Thriruvananthapuram, India, 695 032
- Jothydev's Diabetes & Research Center
-
-
A.P.
-
Hyderabad, A.P., India, 500 012
- Osmania General Hospital
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, India, 500016
- Sunshine Hospital
-
Hyderabad, Andhra Pradesh, India, 500034
- Care Outpatient Centre
-
Hyderabad, Andhra Pradesh, India, 500072
- Ramdev Rao Hospital
-
-
Assam
-
Guwahati, Assam, India, 781033
- Apollo Excelcare Hospital, Guwahati
-
Guwahati, Assam, India, 781033
- Apollo Excelcare Hospital
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380006
- HCG Hospitals
-
Ahmedabad, Gujarat, India, 380007
- Dr. Jivraj Mehta Health Foundation
-
-
Haryana
-
Rohtak, Haryana, India, 124001
- PGIMS Rohtak
-
-
Karnataka
-
Bangalore, Karnataka, India, 560054
- Ramaiah Memorial Hospital
-
Bangalore, Karnataka, India, 560092
- Lifecare Hospital and Research Centre
-
-
Kerala
-
Kozhikode, Kerala, India, 673008
- Calicut Medical College
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, India, 452010
- TOTALL Diabetes Hormone Institute
-
-
Maharashtra
-
Goa, Maharashtra, India, 403 202
- Goa Medical College
-
Mumbai, Maharashtra, India, 400016
- P D Hinduja National Hospital and Medical Research Centre
-
Mumbai, Maharashtra, India, 400058
- BSES MG Hospital
-
Mumbai, Maharashtra, India, 400008
- BYL Nair Hospital and T N Medical College Department of endo
-
Mumbai, Maharashtra, India, 4000016
- P D Hinduja National Hospital and Medical Research Centre
-
Mumbai, Maharashtra, India, 400078
- Fortis Hospital Mulund
-
Mumbai, Maharashtra, India, 400078
- Fortis Hospital, Mulund, Mumbai
-
Pune, Maharashtra, India, 411040
- Inamdar Multispeciality Hospital
-
Pune, Maharashtra, India, 411021
- chelleram Diabetes Institute
-
-
New Delhi
-
New Dehli, New Delhi, India, 110029
- All India Institute of Medical Sciences
-
-
Odisha
-
Bhubaneswar, Odisha, India, 751019
- Kanungo Institute of Diabetes Specialities Pvt Ltd
-
-
Punjab
-
Ludhiana, Punjab, India, 141008
- Christian Medical College and Hospital
-
Ludhiana, Punjab, India, 141001
- Dayanand Medical College & Hospital
-
Mohali, Punjab, India, 160062
- Fortis Heart Institute and Multispeciality Hospital
-
-
Rajasthan
-
Jaipur, Rajasthan, India, 302006
- Diabetes, Thyroid and Endocrine Centre
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, India, 600086
- Madras Diabetes Research Foundation
-
Coimbatore, Tamil Nadu, India, 641018
- Kg Hospital and Post Graduate Medical Institute
-
Ranipet, Tamil Nadu, India, 632517
- Christian Medical College Hospital, Vellore
-
Vellore, Tamil Nadu, India, 632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad, Telangana, India, 500012
- Osmania General Hospital
-
Hyderabad, Telangana, India, 500072
- Ramdev Rao Hospital
-
Hyderabad, Telangana, India, 500003
- Gandhi Hospital & Medical college
-
-
West Bengal
-
Kolkata, West Bengal, India, 700054
- Apollo Gleneagles Hospital
-
Kolkata, West Bengal, India, 700054
- Apollo Multispeciality Hospital, Kolkata
-
Kolkata, West Bengal, India, 700020
- SSKM
-
-
-
-
-
Haifa, Israel, 31096
- Rambam MC - Diabetes and obesity center of excellence
-
Jerusalem, Israel, 91120
- Hadassah Ein Karam MC - Diabetes Unit
-
Jerusalem, Israel, 93106
- Clalit HMO Hamoshava Jerusalem
-
Kfar Saba, Israel, 44281
- Meir MC - Diabetes unit
-
Nahariya, Israel, 22100
- Western Galilee MC - Institute of Diabetes
-
Petah Tikva, Israel, 49100
- Rabin MC Beilinson - Endo unit
-
Tel Aviv, Israel, 6423906
- Sourasky MC - Institute of Endocrinology, metabolism and hypertension
-
Tel Litwinsky, Israel, 52621
- Sheba MC - Endocrinology Clinic
-
Tel Litwinsky, Israel, 52621
- Endrocrinolgy Clinic - Sheba Medical Center
-
Tel Litwinsky, Israel, 5265601
- Sheba MC - Cardiology Clinical Research Unit
-
Tel Litwinsky, Israel, 5265601
- Sheba Medica Center - Clinical Research Unit
-
-
-
-
-
Chieti Scalo, Italy, 66100
- Università degli studi G. D'Annunzio Chieti Pescara - CAST
-
Milan, Italy, 20138
- Centro Cardiologico Monzino
-
Napoli, Italy, 80131
- Università Federico II Dip. di Med. Clinica e Chirurgia Ed 1
-
Padua, Italy, 35128
- Azienda Ospedaliera di Padova Malatt.Metab
-
Palermo, Italy, 90127
- Dip. di Medicina Interna Policlinico Universitario Palermo
-
Palermo, Italy, 90127
- Policlinico Universitario Paolo Giaccone
-
Roma, Italy, 00133
- Policlinico Universitario Tor Vergata
-
-
BA
-
Bari, BA, Italy, 70124
- A.O.U. Consorziale Policlinico di Bari
-
-
Cz
-
Catanzaro, Cz, Italy, 88100
- Azienda Ospedaliero-Universitaria Renato Dulbecco
-
-
LU
-
Lucca, LU, Italy, 55100
- Azienda Unita' Sanitaria Locale Toscana Nord Ovest - Cittadella della Salute Campo di Marte
-
-
MI
-
Milan, MI, Italy, 20132
- Istituto Scientifico San Raffaele
-
-
RM
-
Roma, RM, Italy, 00161
- Policlinico Umberto I Seconda Clinica Medica
-
-
Umbria
-
Perugia, Umbria, Italy, 06129
- Azienda Ospedaliera di Perugia;Ospedale S. Maria della Misericordia
-
-
-
-
-
Bunkyo-ku, Tokyo, Japan, 113-8655
- The University of Tokyo Hospital, Diabetes and Metabolic
-
Chiba, Japan, 271-0077
- New Tokyo Heart Clinic_Matsudo-shi, Chiba,
-
Ehime, Japan, 790-0024
- Ehime Prefectural Central Hospital
-
Ehime, Japan, 790-0024
- Ehime Prefectural Central Hosp
-
Fukui, Japan, 910-0846
- Fukui Prefectural Hospital
-
Fukuoka, Japan, 816-0864
- Fukuoka Tokushukai Hospital
-
Ibaraki, Japan, 311-0113
- Naka Kinen Clinic
-
Ibaraki, Japan, 311-0113
- Naka Kinen Clinic_Internal medicine
-
Kyoto, Japan, 611-0041
- Uji Tokushukai Medical Center_Cardiovascular Medicine
-
Kyoto-shi, Kyoto, Japan, 606-8507
- Kyoto University Hospital
-
Miyagi, Japan, 983-0039
- Shinden Higashi Clinic_Miyagi
-
Nagano, Japan, 390-8621
- Shinshu University Hospital
-
Osaka, Japan, 569-1045
- Takatsuki Red Cross Hospital
-
Osaka, Japan, 564-0013
- Saiseikai Suita Hospital
-
Osaka, Japan, 565-0871
- Osaka University Hospital_Osaka
-
Osaka, Japan, 569-1045
- Takatsuki Red Cross Hospital_Diabetes and Endocrine Div.
-
Osaka, Japan, 574-0074
- Nozaki Tokushukai Hospital_Internal medicine
-
Saga-shi, Saga, Japan, 849-8501
- Saga University Hospital, Department of Cardiology
-
Sapporo-shi, Hokkaido, Japan, 062-0003
- Hanaoka Seishu Memorial Hosp._Cardiovascular Medicine
-
Takamatsu-shi, Kagawa, Japan, 760-8557
- Kagawa Prefectural Central Hospital, Cardiovascular Medicine
-
Tochigi, Japan, 323-0022
- Oyama East Clinic
-
Tochigi, Japan, 323-0022
- Oyama East Clinic_Internal Medicine
-
Tokorozawa-shi, Saitama, Japan, 356-1142
- Tokorozawa Heart Center
-
Tokyo, Japan, 113-8431
- Juntendo University Hospital
-
Tokyo, Japan, 192-0918
- Minamino Cardiovascular Hospital
-
Tokyo, Japan, 113-8431
- Juntendo University Hospital_Tokyo
-
Tokyo, Japan, 177-0041
- Sugawara Clinic
-
Tokyo, Japan, 196-0003
- Tokyo Nishi Tokushukai Hospital
-
Tokyo, Japan, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japan, 192-0918
- Minamino Cardiovascular Hospital_Cardiovascular medicine
-
Tokyo, Japan, 196-0003
- Tokyo Nishi Tokushukai Hospital_Cardiovascular medicine
-
-
Kumamoto, Japan
-
Kumamoto, Kumamoto, Japan, Japan, 862-0976
- Jinnouchi Hospital_Internal Medicine
-
Kumamoto, Kumamoto, Japan, Japan, 862-0976
- Jinnouchi Hospital
-
-
Miyazaki
-
Miyazaki, Miyazaki, Japan, 880-0034
- Heiwadai Hospital_Internal Medicine
-
-
-
-
-
Alor Star, Malaysia, 05460
- Hospital Sultanah Bahiyah
-
Kuching, Malaysia, 93586
- Sarawak General Hospital
-
Sarawak, Malaysia, 98000
- Hospital Miri
-
Seremban, Malaysia, 70300
- Hospital Tuanku Jaafar
-
-
Kedah
-
Alor Star, Kedah, Malaysia, 05460
- Hospital Sultanah Bahiyah
-
-
Kelantan
-
Kota Bharu, Kelantan, Malaysia, 15586
- Hospital Raja Perempuan Zainab II
-
Kota Bharu, Kelantan, Malaysia, 16150
- Hospital Universiti Sains Malaysia_Kota Bharu, Kelantan
-
-
Kuala Lumpur
-
Lembah Pantai, Kuala Lumpur, Malaysia, 59100
- University Malaya Medical Centre
-
-
Putrajaya
-
Putrajaya, Putrajaya, Malaysia, 62250
- Hospital Putrajaya
-
-
Sarawak
-
Kota Samarahan, Sarawak, Malaysia, 94300
- Sarawak Heart Centre
-
Miri, Sarawak, Malaysia, 98000
- Hospital Miri
-
-
Selangor
-
Sungai Buloh, Selangor, Malaysia, 47000
- University Technology MARA (UiTM) - Puncak Alam
-
Sungai Buloh, Selangor, Malaysia, 47000
- University Technology MARA (UiTM) - Sg Buloh
-
-
-
-
-
Aguascalientes, Mexico, 20230
- Centro de Investigación Cardiometabólica de Aguascalientes
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44600
- Inst. Jaliscience de Investigacion en Diabetes y Obesidad SC
-
Guadalajara, Jalisco, Mexico, 44650
- Consultorio Arechavaleta Granell María del Rosario
-
-
México, D.F.
-
Tlalpan, México, D.F., Mexico, 14080
- Centro de Atención Integral al Paciente con Diabetes
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64060
- Cardiolink Clin Trials S.C.
-
Monterrey, Nuevo León, Mexico, 64020
- Internal Medicine Clin Trials
-
San Nicolás de los Garza, Nuevo León, Mexico, 66465
- Unidad Medica para la Salud Integral (UMSI)
-
-
Sonora
-
Hermosillo, Sonora, Mexico, 83280
- Investigación Médica Sonora S.C.
-
-
Yucatán
-
Mérida, Yucatán, Mexico, 97000
- Eme Red Hospitalaria
-
Mérida, Yucatán, Mexico, 97070
- Medical Care and Research S. A de C.V
-
-
-
-
-
Amersfoort, Netherlands, 3813 TZ
- Meander Medisch Centrum
-
Amsterdam, Netherlands, 1081 HV
- Amsterdam UMC Lokatie VUMC
-
Apeldoorn, Netherlands, 7334 DZ
- Gelre Ziekenhuizen Apeldoorn
-
Delft, Netherlands, 2625 AD
- Reinier de Graaf Gasthuis
-
Eindhoven, Netherlands, 5631 BM
- Maxima Medisch Centrum
-
Groningen, Netherlands, 9728 NT
- Martini Ziekenhuis
-
Hoogeveen, Netherlands, 7909 AA
- Bethesda Diabetes Research Center en Bethesda ziekenhuis
-
Maastricht, Netherlands, 6229 HX
- Maastricht Universitair Medisch Centrum
-
Nijmegen, Netherlands, 6525 GA
- Radboudumc
-
Utrecht, Netherlands, 3584 CX
- Universitair Medisch Centrum Utrecht
-
-
-
-
-
Bacau, Romania, 600154
- CMI Dr. Pletea Noemi SRL
-
Bucharest, Romania, 051811
- Diabet Med SRL
-
Galati, Romania, 800578
- Clinical Emergency Sf. Apostol Andrei Hospital
-
Iași, Romania, 700111
- Spitalul Clinic Judetean de Urgente Sf. Spiridon
-
Sibiu, Romania, 550371
- SC Gensan SRL, Policlinica ASTRA
-
-
Cluj
-
Cluj-Napoca, Cluj, Romania, 400006
- Clinic of Diabetes Cluj
-
-
Dâmbovița County
-
Târgovişte, Dâmbovița County, Romania, 130083
- Spitalul Judetean de Urgenta Targoviste
-
-
Mureș County
-
Târgu Mureş, Mureș County, Romania, 540136
- Spitalul Clinic Judetean de Urgenta Targu Mures
-
Târgu Mureş, Mureș County, Romania, 540142
- Sc Mediab Srl
-
-
Prahova
-
Ploieşti, Prahova, Romania, 100342
- CMI Dr. Busegeanu Mihaela Magdalena
-
Ploieşti, Prahova, Romania, 100018
- Novus Medical Clinica SRL
-
-
-
-
-
Barnaul, Russia, 656045
- City Hospital #5
-
Kazan', Russia, 420012
- Kazan Federal University
-
Kazan', Russia, 420111
- LLC "Clinic of Aesthetic Medicine & Laser Technologies"
-
Kemerovo, Russia, 650066
- SAHI Kuzbass Hospital(former Regional clinical hospital)
-
Moscow, Russia, 119435
- Setchenov First Moscow State Medical University
-
Moscow, Russia, 117292
- Friendship University of Russia
-
Novosibirsk, Russia, 630087
- State Novosibirsk Regional Clinical Hospital
-
Novosibirsk, Russia, 630099
- Limited Law Company "Healthy Family" Medicine Center"
-
Penza, Russia, 440052
- Penza Regional Clinical Hospital named after N.N. Burdenko
-
Saint Petersburg, Russia, 191119
- SPb SBHI City Outpatient clinic #37
-
Saint Petersburg, Russia, 194156
- Aurora MedFort LLC
-
Saint Petersburg, Russia, 194354
- City Consultative & Diagnostic Centre #1
-
Saint Petersburg, Russia, 194354
- SPb SBHI City Multifield Hospital #2
-
Saint Petersburg, Russia, 197110
- Consultative & Diagnostic Center with a Outpatient Hospital
-
Saratov, Russia, 410053
- Saratov Regional Clinical Hospital
-
Saratov, Russia, 410039
- Regional clinical cardiology dispensary
-
Tomsk, Russia, 634050
- Siberian State Medical University
-
Ulyanovsk, Russia, 432063
- Ulianovsk Regional Clinical Hospital
-
Yaroslavl, Russia, 150062
- Yaroslavl Regional Hospital
-
Yoshkar-Ola, Russia, 424004
- Polyclinic #2 in Yoshkar-Ola
-
-
Russia
-
Tyumen, Russia, Russia, 625023
- Tumen State Medical University
-
-
-
-
-
Belgrade, Serbia, 11000
- Military Medical Academy
-
Belgrade, Serbia, 11000
- Endocrinology, Diabetes and Metabolism Diseases Clinic
-
Belgrade, Serbia, 11000
- CHC Zvezdara, Clinical department for endocrinology
-
Kragujevac, Serbia, 34000
- Clinical Centre Kragujevac, Internal Diseases Clinic, Endocrinology department
-
Niš, Serbia, 18000
- Clinical Centre Nis, Endocrinology, Diabetes and Metabolism
-
Zaječar, Serbia, 19000
- Policlinic for diabetes
-
-
Vojvodina
-
Novi Sad, Vojvodina, Serbia, 21000
- Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.
-
-
-
-
-
Bratislava, Slovakia, 831 01
- Metabolicke Centrum MUDr. Katariny Raslovej s.r.o.
-
Bratislava, Slovakia, 83103
- MediTask, s.r.o
-
Bratislava, Slovakia, 833 05
- Nemocnica akademika L. Derera, UNB
-
Košice, Slovakia, 040 22
- Cardio D&R, s.r.o.
-
Košice, Slovakia, 040 01
- HUMAN-CARE, s.r.o.
-
Krompachy, Slovakia, 05342
- Nemocnica Krompachy spol. s r.o Diabetol. amb. MD Gmitrov
-
Nitra, Slovakia, 949 01
- Diabetologicka ambulancia MUDr. Katarina Plevova, s.r.o.
-
Poprad, Slovakia, 05801
- Dentavia s.r.o.
-
Prievidza, Slovakia, 97101
- MUDr. Jan Culak, s.r.o.
-
Rimavská Sobota, Slovakia, 97901
- Kardiologicka a interna ambulancia
-
Rožňava, Slovakia, 04801
- Tatratrial s.r.o.
-
Vrútky, Slovakia, 038 61
- IRIDIA s.r.o.
-
-
-
-
Gauteng
-
Benoni, Gauteng, South Africa, 1501
- Diabetes Care Centre & CDE Centre
-
Johannesburg, Gauteng, South Africa, 1820
- Deepak Lakha
-
Johannesburg, Gauteng, South Africa, 1827
- Hemant Makan
-
Johannesburg, Gauteng, South Africa, 1818
- Soweto Clinical Trial Centre
-
Johannesburg, Gauteng, South Africa, 1619
- Peermed Clinical Trial Centre
-
Johannesburg, Gauteng, South Africa, 1829
- Deepak Lakha
-
Johannesburg, Gauteng, South Africa, 2198
- Centre for Diabetes
-
Pretoria, Gauteng, South Africa, 0083
- Dr Seeber
-
Pretoria, Gauteng, South Africa, 0181
- Prof P. Joshi
-
-
KwaZulu-Natal
-
Berea, KwaZulu-Natal, South Africa, 4091
- Dr H Bacus
-
Durban, KwaZulu-Natal, South Africa, 4450
- Dr Pillay's Rooms
-
Durban, KwaZulu-Natal, South Africa, 4092
- Dr A Amod
-
Durban, KwaZulu-Natal, South Africa, 4170
- Dr T Padayachee
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7925
- Diabetes Clinical Trials Unit
-
Cape Town, Western Cape, South Africa, 7925
- UCT Clinical Research Centre
-
-
-
-
-
Gyeonggi-do, South Korea, 13620
- Seoul National University Bundang Hospital
-
Gyeonggi-do, South Korea, 471-101
- Hanyang University Guri Hospital
-
Seoul, South Korea, 05505
- Asan Medical Center
-
Seoul, South Korea, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, South Korea, 06591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul, South Korea, 02841
- Korea University Anam Hospital
-
Seoul, South Korea, 06591
- Seoul Saint Mary's Hospital
-
Seoul, South Korea, 139-827
- Nowon Eulji Medical Center, Eulji University
-
-
-
-
-
A Coruña, Spain, 15006
- Complejo Hospitalario Universitario a Coruña
-
Antequera, Spain, 29200
- Hospital Comarcal de Antequera
-
Barcelona, Spain, 08003
- Hospital del Mar
-
Burela de Cabo, Spain, 27880
- Hospital Público da Mariña
-
Córdoba, Spain, 14004
- Hospital Reina Sofia
-
Las Palmas de Gran Canaria, Spain, 35010
- Hospital Univ. de Gran Canaria Doctor Negrín
-
Lugo, Spain, 27004
- Hospital Ribera Polusa
-
Málaga, Spain, 29006
- Hospital Clínico Virgen de la Victoria
-
Pozuelo de Alarcón, Spain, 28223
- Hospital Universitario Quirónsalud Madrid
-
Pozuelo de Alarcón, Spain, 28223
- Hospital Quirón
-
Sanlúcar de Barrameda, Spain, 11540
- Hospital Virgen del Camino - Sanlúcar de Barrameda
-
Santander, Spain, 39008
- Hospital Universitario Marqués de Valdecilla
-
Santiago de Compostela, Spain, 15706
- Complejo Hospitalario Universitario de Santiago
-
Seville, Spain, 41009
- Hospital Virgen de la Macarena
-
-
Madrid
-
Alcorcón, Madrid, Spain, 28922
- Hospital Fundación Alcorcón
-
-
-
-
-
Changhua, Taiwan, 500
- Changhua Christian Hospital_Metabolic Dept.
-
Taichung, Taiwan, 402
- Chung Shan Medical University Hospital
-
Taoyuan District, Taiwan, 333
- Chang Gung Medical Foundation - Linkou Branch
-
-
-
-
-
Bangkok, Thailand, 10400
- Phramongkutklao Hospital
-
Bangkok, Thailand, 10400
- Rajavithi Hospital
-
Bangkok, Thailand, 10330
- Police General Hospital
-
Bangkok, Thailand, 10400
- Ramathibodi Hospital-Cardiovascular metabolic Center
-
Bangkok, Thailand, 10330
- King Chulalongkorn Memorial Hospital_Endocrinology
-
Bangkok, Thailand, 10700
- SI-Dvs of Endocrinology
-
Bangkok, Thailand, 10700
- Siriraj Hospital-Cardio
-
Bangkok, Thailand, 10400
- Rajavithi Hospital_Diabetes and Endocrinology
-
Nakhon Ratchasima, Thailand, 30000
- Maharat Nakhon Ratchasima Hospital
-
-
Had-Yai
-
Songkhla, Had-Yai, Thailand, 90110
- Songklanagarind Hospital
-
-
Mueang Chiang Mai
-
Chiang Mai, Mueang Chiang Mai, Thailand, 50200
- Maharaj Nakorn Chiang Mai Hospital_Endocrilogy
-
-
-
-
-
Adana, Turkey (Türkiye), 01000
- T.C. Saglık Bakanlıgı Adana Sehir Egitim ve Arastirma Hastan
-
Ankara, Turkey (Türkiye), 06010
- Gulhane Egitim Arastirma Hastanesi
-
Bursa, Turkey (Türkiye), 16310
- T.C. Saglik Bakanligi Bursa Il Saglik Mudurlugu Yuksek Ihtıs
-
Bursa, Turkey (Türkiye), 16310
- Bursa Yüksek İhtisas Eğitim ve Araştırma Merkezi-Kardiyoloji
-
Erzurum, Turkey (Türkiye), 25240
- Atatürk Üniversitesi Araştırma Hastanesi- Endokrinoloji
-
Eskişehir, Turkey (Türkiye), 26040
- Eskişehir Osmangazi Üniversitesi Sağlık, Uygulama ve Araştırma Hastanesi
-
Hatay, Turkey (Türkiye), 31060
- Hatay Mustafa Kemal Universitesi Saglik Uygulama ve Arastirm
-
Istanbul, Turkey (Türkiye), 34303
- Kanuni Sultan Suleyman Egitim ve Arastirma Hastanesi
-
Istanbul, Turkey (Türkiye), 34096
- Haseki Egitim ve Arastirma Hastanesi_ISTANBUL
-
Istanbul, Turkey (Türkiye), 34722
- Göztepe Prof. Dr.Süleyman Yalçın Şehir Hastanesi- Dahiliye
-
Izmir, Turkey (Türkiye), 35340
- Dokuz Eylül Üniversitesi Araştırma Uygulama Hastanesi-Endokrinoloji
-
Kayseri, Turkey (Türkiye), 38039
- Erciyes Üniversitesi Hastanesi- Nefroloji
-
Sivas, Turkey (Türkiye), 58140
- Sivas Cumhuriyet Üniversitesi Hastanesi -Endokrinoloji
-
Trabzon, Turkey (Türkiye), 61080
- Karadeniz University School of Medicine-Adult Endocrinology
-
Yüreğir/Adana, Turkey (Türkiye), 1370
- Adana Şehir Eğitim ve Araştırma Hastanesi
-
-
-
-
-
Cherkasy, Ukraine, 18009
- Cherkasy Regional Clinical Hospital - Endocrinology department
-
Chernivtsi, Ukraine, 58022
- Chernivtsi Regional Clinical Hospital - Endo Outpatient department
-
Dnipro, Ukraine, 49005
- Dnipropetrovsk Regional Clinical Hospital named after І.І.Mechnikov - Endocrinology therapy department
-
Kyiv, Ukraine, 03049
- Kyiv Railway Clinical Hospital #2 - day care department
-
Kyiv, Ukraine, 04053
- Centre of Innovative Medical Technologies of NASU - Therapeutic and Endocrinology Department
-
Lviv, Ukraine, 79010
- Lviv Regional Clinical Diagnostic and Treatment Endocrinology Centre - Outpatient department
-
Odesa, Ukraine, 65025
- Odesa Regional Clinical Hospital - Endocrinology department
-
Poltava, Ukraine, 36039
- City Clinical Hospital #1 (Poltava) - Therapeutic department
-
Uzhhorod, Ukraine, 88000
- Transcarpathian Regional Clinical Hospital named after A.Novak - Endocrinology department
-
Zhytomyr, Ukraine, 10002
- Zhytomir Regional Clinical Hospital - Endocrinology department
-
-
-
-
-
Aberdeen, United Kingdom, AB25 2ZN
- Aberdeen Royal Infirmary
-
Belfast, United Kingdom, BT12 6BA
- Royal Victoria Hospital
-
Bradford-on-Avon, United Kingdom, BA15 1DQ
- The Health Centre
-
Bristol, United Kingdom, BS10 5NB
- Southmead Hospital
-
Cambridge, United Kingdom, CB2 0QQ
- Addenbrooke's Hospital_Cambridge
-
Chippenham, United Kingdom, SN15 1HP
- Hathaway Surgery
-
Coventry, United Kingdom, CV2 2DX
- WISDEM Centre
-
Edinburgh, United Kingdom, EH4 2XU
- Western General Hospital
-
Glasgow, United Kingdom, G51 4TF
- Queen Elizabeth University Hospital
-
Glasgow, United Kingdom, G31 2ER
- Glasgow Royal Infirmary
-
Harrogate, United Kingdom, HG2 7SX
- Harrogate District Hospital
-
Hinckley, United Kingdom, LE10 2SE
- Burbage Surgery
-
Hull, United Kingdom, HU3 2JZ
- Hull Royal Infirmary
-
London, United Kingdom, NW3 2QG
- Royal Free - Diabetes
-
Manchester, United Kingdom, M8 5RB
- North Manchester General Hospital - Diabetes Centre
-
Norfolk, United Kingdom, NR4 7UQ
- Norfolk and Norwich University Hospital
-
Plymouth, United Kingdom, PL6 8DH
- University Dept of Medicine, Derriford Hospital, Plymouth
-
Redhill, United Kingdom, RH1 5RH
- East Surrey Hospital
-
Soham, United Kingdom, CB7 5JD
- The Staploe Medical Centre
-
Swansea, United Kingdom, SA2 8PP
- Joint Clinical Research Facility - Swansea
-
-
Surrey
-
Addlestone, Surrey, United Kingdom, KT15 2BH
- Crouch Oak Family Practice
-
-
-
-
Alabama
-
Montgomery, Alabama, United States, 36106
- Chambliss Clinical Trials, LLC
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
- Medical Investigations, Inc.
-
Searcy, Arkansas, United States, 72143
- Unity Health-Searcy Medical Center
-
-
California
-
Fresno, California, United States, 93721-1443
- B&K Medical Research Center
-
Fullerton, California, United States, 92835
- University of Vermont Medical Center
-
La Jolla, California, United States, 92037
- Scripps Whittier Diabetes Inst
-
La Mesa, California, United States, 91942
- Diabetes & Endocrine Associates
-
Lancaster, California, United States, 93534
- First Valley Medical Group
-
Los Alamitos, California, United States, 90720
- Pacific Clinical Studies
-
Mission Hills, California, United States, 91345
- Facey Medical Foundation
-
Monterey, California, United States, 93940
- Monterey Endocrine & Diabetes Institute, Inc
-
Palm Springs, California, United States, 92262
- Desert Oasis Hlthcr Med Group
-
San Diego, California, United States, 92111
- San Diego Family Care
-
Torrance, California, United States, 90502
- Lundquist Inst-Biomed Innovtn
-
Ventura, California, United States, 93003
- Coastal Metabolic Research Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Rocky Mount Reg VA Med-DN
-
Denver, Colorado, United States, 80246
- Creekside Endocrine Associates, PC
-
Golden, Colorado, United States, 80401
- New West Physicians,Inc.
-
-
Florida
-
Boca Raton, Florida, United States, 33433
- East Coast Medical Associates, Inc.
-
New Port Richey, Florida, United States, 34652
- Suncoast Clin Res Port Richey
-
Orlando, Florida, United States, 32804
- AdventHealth Diab Inst
-
-
Georgia
-
Alpharetta, Georgia, United States, 30022
- Ellipsis Group
-
Lawrenceville, Georgia, United States, 30046
- Physicians Research Assoc. LLC
-
Roswell, Georgia, United States, 30076
- Endo Res Solutions Inc
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96814
- East West Med Res Inst
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83404-7596
- Rocky Mountain Diab&Osteo Ctr
-
-
Illinois
-
Gurnee, Illinois, United States, 60031
- Clinical Invest Special_Gurnee
-
-
Indiana
-
Franklin, Indiana, United States, 46131
- American Health Network of IN LLC_Franklin
-
Greenfield, Indiana, United States, 46140
- American Health Network of Indiana, LLC_Greenfield
-
Michigan City, Indiana, United States, 46360
- Franciscan Health Michigan City
-
Muncie, Indiana, United States, 47304
- American Health Network of IN LLC
-
-
Iowa
-
West Des Moines, Iowa, United States, 50266
- Iowa Diab & Endo Res Center
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- The Research Group of Lexington LLC
-
Louisville, Kentucky, United States, 40213
- L-MARC Research Center
-
Louisville, Kentucky, United States, 40206
- Robley Rex VA Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University Health Sciences Center
-
Slidell, Louisiana, United States, 70461-4231
- Ileana J Tandron APMC
-
-
Michigan
-
Buckley, Michigan, United States, 49620
- Northern Pines Hlth Ctr, PC
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Methodist Phys. Clinic
-
Omaha, Nebraska, United States, 68198-3020
- Univ of Nebraska Medical CTR
-
-
Nevada
-
Las Vegas, Nevada, United States, 89128
- Palm Research Center Inc-Vegas
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03766
- Dartmouth-Hitchcock Med Ctr
-
Nashua, New Hampshire, United States, 03060
- Southern New Hampshire Diabetes and Endocrinology
-
-
New York
-
Albany, New York, United States, 12203
- AMC Community Endocrinology
-
West Seneca, New York, United States, 14224
- Southgate Medical Group, LLP
-
Westfield, New York, United States, 14787
- Great Lakes Medical Research
-
-
North Carolina
-
Asheville, North Carolina, United States, 28803
- Mountain Diabetes & Endocrine Center
-
Burlington, North Carolina, United States, 27215
- Kernodle Clin Dpt-Pvt Diagnost
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina
-
Greensboro, North Carolina, United States, 27408
- PharmQuest Life Sciences LLC
-
Greenville, North Carolina, United States, 27834
- Physicians East Endocrinology
-
New Bern, North Carolina, United States, 28562
- Eastern Nephr Assoc, PLLC
-
Whiteville, North Carolina, United States, 28472
- Whiteville Medical Associates
-
Wilmington, North Carolina, United States, 28401
- Accellacare
-
-
North Dakota
-
Fargo, North Dakota, United States, 58104
- Lillestol Research LLC
-
-
Ohio
-
Marion, Ohio, United States, 43302
- Awasty Research Network,LLC
-
Maumee, Ohio, United States, 43537
- Advanced Med Res Maumee
-
Mentor, Ohio, United States, 44060
- Your Diabetes Endocrine Nutrition Group, Inc.
-
Twinsburg, Ohio, United States, 44087
- Twinsburg Family Health Center
-
-
Oklahoma
-
Norman, Oklahoma, United States, 73072
- Lynn Institute of Norman
-
-
Pennsylvania
-
Beaver, Pennsylvania, United States, 15009
- Heritage Valley Medical Group Inc
-
McMurray, Pennsylvania, United States, 15317
- Primary Care Research South, Inc
-
Philadelphia, Pennsylvania, United States, 19114
- Aria Endocrine Metabolic Assoc
-
Pittsburgh, Pennsylvania, United States, 15243
- Preferred Primary Care Physicians Inc.
-
-
South Carolina
-
Murrells Inlet, South Carolina, United States, 29576
- The Diabetes Center, LLC
-
Myrtle Beach, South Carolina, United States, 29572
- Carolina Health Specialists
-
Spartanburg, South Carolina, United States, 29303
- Spartanburg Medical Research
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37411
- Univ Diab & Endo Consultants
-
Chattanooga, Tennessee, United States, 37404
- Michael L Reeves, MD
-
Kingsport, Tennessee, United States, 37660
- Holston Medical Group
-
Nashville, Tennessee, United States, 37203
- MidState Endocrine Associates
-
Nashville, Tennessee, United States, 37203
- InvestiClin Research
-
Nashville, Tennessee, United States, 37212
- Vanderbilt Diab Obes Clin Tri
-
Tullahoma, Tennessee, United States, 37388
- Trinity Clinical Research LLC
-
-
Texas
-
Arlington, Texas, United States, 76012-4637
- Arlington Family Res. Ctr Inc
-
Austin, Texas, United States, 78705
- Central Texas Clinical Research
-
Austin, Texas, United States, 78749
- Texas Diabetes & Endocrinology
-
Austin, Texas, United States, 78731
- Texas Diabetes & Endocrinology, P.A._Austin
-
Dallas, Texas, United States, 75230
- Velocity Clinical Res-Dallas
-
Dallas, Texas, United States, 75390-9302
- UT Southwestern Med Cntr
-
Fort Worth, Texas, United States, 76132
- Diabetes and Thyroid Ctr of FW
-
Houston, Texas, United States, 77024
- PrimeCare Medical Group
-
Houston, Texas, United States, 77061
- Synergy Groups Medical
-
Longview, Texas, United States, 75605
- DCOL Ctr for Clin Res
-
Midland, Texas, United States, 79707
- Midland Clinical Research Center
-
Round Rock, Texas, United States, 78681
- Texas Diabetes & Endocrinology, P.A._Austin
-
Sugar Land, Texas, United States, 77478
- Simcare Medical Research, LLC
-
Waco, Texas, United States, 76708
- Hillcrest Family Health Center
-
-
Virginia
-
Richmond, Virginia, United States, 23219
- Dominion Medical Associates
-
Winchester, Virginia, United States, 22601-3834
- Selma Medical Associates
-
-
Wisconsin
-
Kenosha, Wisconsin, United States, 60031
- Clinical Investigation Spec. Kenosha
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female, age equal to or above 50 years at the time of signing informed consent
- Diagnosed with type 2 diabetes mellitus
- HbA1c 6.5% - 10.0% (47 - 86 mmol/mol) (both inclusive) (latest available and no more than 30 days old local laboratory assessment based on medical records or point of care measurement)
At least one of the below conditions (a-d):
a) Coronary heart disease defined as at least one of the following: i. Prior myocardial infarction ii. Prior coronary revascularisation procedure iii. 50% or above stenosis in coronary artery documented by cardiac catheterisation, computerized tomography coronary angiography iv. Coronary heart disease with ischaemia documented by stress test with any imaging modality b) Cerebrovascular disease defined as at least one of the following: i. Prior stroke ii. Prior carotid artery revascularisation procedure iii.50% or above stenosis in carotid artery documented by X-ray angiography, magnetic resonance angiography, computerized tomography angiography or Doppler ultrasound c) Symptomatic peripheral artery disease (PAD) defined as at least one of the following: i. Intermittent claudication with an Ankle-brachial index (ABI) below 0.85 at rest ii. Intermittent claudication with a 50% or above stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, magnetic resonance angiography, computerized tomography angiography or Doppler ultrasound iii. Prior peripheral artery (excluding carotid) revascularization procedure iv. Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g. trauma or osteomyelitis) d) Chronic kidney disease defined as: i. eGFR below 60 mL/min/1.73 m^2 (based on medical records using latest available and no more than 6 months old assessment)
Exclusion Criteria:
- Any of the following: myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within the past 60 days prior to the day of screening
- Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
- Heart failure presently classified as being in New York Heart Association Class IV
- Treatment with any glucagon-like peptide-1 receptor agonist within 30 days before screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Oral semaglutide
One tablet daily for 3.5 to 5 years
|
Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state
|
|
Placebo Comparator: Placebo
One tablet daily for 3.5 to 5 years
|
Placebo tablets to be taken with water at the same time every morning in a fasting state
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants From Randomization to First Occurrence of a Major Adverse Cardiovascular Event (MACE), a Composite Endpoint Consisting of: Cardiovascular (CV) Death/Non-fatal Myocardial Infarction/Non-fatal Stroke
Time Frame: From randomisation (week 0) up to week 265
|
Number of participants with first occurrence of EAC (event adjudication committee) confirmed major adverse cardiovascular event (MACE), a composite end-point.
i.e., from time of randomization to first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction and non-fatal stroke combined data during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants From Randomization to First Occurrence of CV Death;Renal Death;Onset of Persistent≥50% Reduction in eGFR(CKD-EPI);Onset of Persistent eGFR(CKD-EPI)<15 mL/Min/1.73m^2;Initiation of Chronic Renal Replacement Therapy
Time Frame: From randomisation (week 0) up to week 265
|
Number of participants with first occurrence of a composite endpoint.
i.e., from time of randomization to first occurrence of CV death, renal death, onset of persistent greater than or equal to (≥) 50% reduction in estimated glomerular filtration rate (eGFR) (chronic kidney disease epidemiology collaboration CKD-EPI), onset of persistent eGFR (CKD-EPI) less than (<)15 milliliters per minute per 1.73 square meters (mL/min/1.73
m^2), initiation of chronic renal replacement therapy (dialysis or kidney transplantation) combined data during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomization to Time of Occurrence of CV Death
Time Frame: From randomisation (week 0) up to week 265
|
Number of participants from time of randomization to time to occurrence of EAC confirmed CV death during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomization to First Occurrence of Major Adverse Limb Events (MALE), a Composite Endpoint Consisting of: Acute Limb Ischemia Hospitalisation/Chronic Limb Ischemia Hospitalisation
Time Frame: From randomisation (week 0) up to week 265
|
Number of participants from randomization to first occurrence of EAC confirmed major adverse limb events (MALE), a composite endpoint consisting of: acute limb ischemia hospitalisation/chronic limb ischemia hospitalisation combined data during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of an Expanded MACE Composite Endpoint Consisting of: CV Death/Non-fatal Myocardial Infarction/ Non-fatal Stroke/Coronary Revascularisation/Unstable Angina Pectoris Requiring Hospitalisation
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to first occurrence of an expanded MACE composite endpoint consisting of: CV death/non-fatal myocardial infarction/ non-fatal stroke/coronary revascularisation/unstable angina pectoris requiring hospitalisation combined data during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of a Composite Endpoint Consisting of : All-cause Death/ Non-fatal MI/ Non-fatal Stroke
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to first occurrence of EAC confirmed composite endpoint consisting of : all-cause death/ non-fatal MI/ non-fatal stroke combined data during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of a Composite Heart Failure Endpoint Consisting of: CV Death/Heart Failure Requiring Hospitalisation/Urgent Heart Failure Visit
Time Frame: From randomisation (week 0) up to week 265
|
Number of participants from randomisation to first occurrence of EAC confirmed composite heart failure endpoint consisting of: CV death/heart failure requiring hospitalisation/urgent heart failure visit combined data during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomization to First Occurrence of CKD Endpoint:Renal Death;Onset of Persistent≥50% Reduction in eGFR (CKD-EPI);Onset of Persistent eGFR(CKD-EPI)<15 mL/Min/1.73 m^2;Initiation of Chronic Renal Replacement Therapy
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomization to first occurrence of CKD endpoint:renal death;onset of persistent≥50% reduction in eGFR (CKD-EPI);onset of persistent eGFR(CKD-EPI)<15 mL/min/1.73
m^2;initiation of chronic renal replacement therapy combined data during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to Time to Occurrence of All-cause Death
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to time to occurrence of EAC confirmed all-cause death during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of Non-fatal Myocardial Infarction (MI)
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to first occurrence of EAC confirmed non-fatal MI during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of Non-fatal Stroke
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to first occurrence of EAC confirmed non-fatal stroke during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of Heart Failure Requiring Hospitalisation or Urgent Heart Failure Visit
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to first occurrence of EAC confirmed heart failure requiring hospitalisation or urgent heart failure visit during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of Coronary Revascularisation
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to first occurrence of coronary revascularisation during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of Unstable Angina Requiring Hospitalisation
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to first occurrence of EAC confirmed unstable angina requiring hospitalisation during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to Time to Occurrence of Renal Death
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to time to occurrence of EAC confirmed renal death during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of Onset of Persistent 50% or More Reduction in eGFR
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to first occurrence of onset of persistent 50% or more reduction in eGFR during in-trial period were observed.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of Onset of Persistent eGFR (CKD-EPI) Below 15 mL/Min/1.73 m^2
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to first occurrence of onset of persistent eGFR (CKD-EPI) below 15 mL/min/1.73
m^2 during in-trial period were observed.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of Initiation of Chronic Renal Replacement Therapy (Dialysis or Kidney Transplantation)
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to first occurrence of EAC confirmed initiation of chronic renal replacement therapy (dialysis or kidney transplantation) during in-trial period were presented.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of Acute Limb Ischemia
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to first occurrence of EAC confirmed acute limb ischaemia hospitalization during in-trial period were presented.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of Chronic Limb Ischemia Hospitalisation
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to first occurrence of EAC confirmed chronic limb ischaemia hospitalization during in-trial period were presented.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Annual Rate of Change in eGFR (CKD-EPI) (Total eGFR Slope)
Time Frame: From randomisation (week 0) up to week 260
|
Annual rate of change in eGFR in terms of chronic kidney disease CKD-EPI were reported during in trial period.
eGFR was calculated using the CKD-EPI formula.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 260
|
|
Change From Baseline in Glycosylated Haemoglobin (HbA1c)
Time Frame: Baseline (Week 0), Week 104
|
Change in HbA1c from baseline (Week 0) up to Week 104 during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
Baseline (Week 0), Week 104
|
|
Change From Baseline in Body Weight
Time Frame: Baseline (Week 0), Week 104
|
Change in body weight from baseline (Week 0) up to Week 104 during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
Baseline (Week 0), Week 104
|
|
Number of Severe Hypoglycaemic Episodes
Time Frame: From randomisation (week 0) up to week 265
|
The number of severe hypoglycaemic episodes (such as the seriousness of hypoglycaemia, contributing factors, seizures, and unconsciousness; classified by American Diabetes Association) observed during the in-trial period were reported in this endpoint.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
|
Number of Participants From Randomisation to First Occurrence of a Severe Hypoglycaemic Episode
Time Frame: From randomisation (week 0) up to week 265
|
The number of participants from randomisation to first occurrence of severe hypoglycaemic episodes (such as the seriousness of hypoglycaemia, contributing factors, seizures, and unconsciousness; classified by American Diabetes Association) during in-trial period were reported.
In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
|
From randomisation (week 0) up to week 265
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Reporting Anchor and Disclosure (1452), Novo Nordisk A/S
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
- McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, Mann JFE, Emerson SS, Poulter NR, Engelmann MDM, Ripa MS, Hovingh GK, Brown-Frandsen K, Bain SC, Cavender MA, Gislum M, David JP, Buse JB; SOUL Study Group. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025 May 29;392(20):2001-2012. doi: 10.1056/NEJMoa2501006. Epub 2025 Mar 29.
- Marx N, Deanfield JE, Mann JFE, Arechavaleta R, Bain SC, Bajaj HS, Bayer Tanggaard K, Birkenfeld AL, Buse JB, Davicevic-Elez Z, Desouza C, Emerson SS, Engelmann MDM, Hovingh GK, Inzucchi SE, Jhund PS, Mulvagh SL, Pop-Busui R, Poulter NR, Rasmussen S, Tu ST, McGuire DK; SOUL Study Group. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. 2025 Jun 10;151(23):1639-1650. doi: 10.1161/CIRCULATIONAHA.125.074545. Epub 2025 Mar 29.
- Borlaug BA, Holse C, Jung MH, Lincoff AM, Mulvagh SL, Staerk-Ostergaard J, Tuttle KR, Petrie MC. Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction. JACC Heart Fail. 2025 Oct 15:102712. doi: 10.1016/j.jchf.2025.102712. Online ahead of print.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 17, 2019
Primary Completion (Actual)
August 23, 2024
Study Completion (Actual)
August 23, 2024
Study Registration Dates
First Submitted
April 11, 2019
First Submitted That Met QC Criteria
April 11, 2019
First Posted (Actual)
April 16, 2019
Study Record Updates
Last Update Posted (Actual)
December 11, 2025
Last Update Submitted That Met QC Criteria
November 24, 2025
Last Verified
November 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EX9924-4473
- 2018-003141-42 (Registry Identifier: European Medicines Agency (EudraCT))
- U1111-1218-5368 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.